AJC Editor's consensus: Selective and nonselective nonsteroidal anti-inflammatory drugs and cardiovascular risk

American Journal of Cardiology

Volumn 106, Issue 6, 2010, Pages 873-884

  Friedewald, Vincent E ^a,b   Bennett, Joel S ^c   Christo, J Paul ^d   Pool, James L ^e   Scheiman, James M ^f   Simon, Lee S ^g   Strand, Vibeke ^h   White, William B ^i,j   Williams, Gary W ^k   Roberts, William C ^l,m  

^a UNIVERSITY OF NOTRE DAME   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

^f UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^g SDG LLC   (United States)

^h STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^j UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^k SCRIPPS CLINIC   (United States)

^l BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^m BAYLOR HEALTH CARE SYSTEM   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOPHENOL; ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ETORICOXIB; IBUPROFEN; LUMIRACOXIB; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PLACEBO; POTASSIUM; PROPIONIC ACID DERIVATIVE; PROTON PUMP INHIBITOR; ROFECOXIB; SALICYLIC ACID DERIVATIVE; TRAMADOL; VALSARTAN;

ACUTE HEART INFARCTION; ADENOMA; ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONFERENCE PAPER; CONSTIPATION; CORONARY ARTERY BYPASS GRAFT; CORONARY STENT; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; DYSPHORIA; ENDOTHELIAL DYSFUNCTION; ENZYME INHIBITION; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL HEMORRHAGE; HEART ARRHYTHMIA; HEART PROTECTION; HUMAN; HYPERTENSION; KIDNEY DYSFUNCTION; LOW DRUG DOSE; NEUROPATHIC PAIN; OSTEOARTHRITIS; PAIN THRESHOLD; PEPTIC ULCER; PRACTICE GUIDELINE; PRIMARY PREVENTION; PRIORITY JOURNAL; RESPIRATION DEPRESSION; RHEUMATOID ARTHRITIS; SEDATION; SIDE EFFECT; STROKE; THROMBOCYTE AGGREGATION; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT DURATION; UREA NITROGEN BLOOD LEVEL; VASOMOTOR REFLEX; CARDIOVASCULAR DISEASES; CHEMICALLY INDUCED; EVIDENCE BASED MEDICINE; HEALTH; PRESCRIPTION; PREVALENCE; PROGNOSIS; RISK; STATISTICS AND NUMERICAL DATA;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARDIOVASCULAR DISEASES; DRUG PRESCRIPTIONS; EVIDENCE-BASED MEDICINE; GLOBAL HEALTH; HUMANS; PREVALENCE; PROGNOSIS; RISK;

EID: 77956307423     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2010.04.006     Document Type: Conference Paper

References (117)

1. Gossel TA. OTC NSAIDs: New Considerations and Options in Treating Osteoarthritis Pain in the Pharmacy Setting. New Hyde Park, New York: The CE Solution.
2. American College of Rheumatology Ad Hoc Group on Use of Selective and Nonselective Nonsteroidal Antiinflammatory Drugs Recommendations for use of selective and nonselective nonsteroidal antiinflammatory drugs: an American College of Rheumatology white paper Arthritis Rheum 59 2008 1058 1073
3. G. Singh, J.G. Fort, J.L. Goldstein, R.A. Levy, P.S. Hanrahan, A.E. Bello, L. Andrade-Ortega, C. Wallemark, N.M. Agrawal, G.M. Eisen, W.F. Stenson, G. Triadafilopoulos SUCCESS-I Investigators Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I study Am J Med 119 2006 255 266
4. S. Bombardieri, P. Cattani, G. Ciabattoni, O. Di Munno, G. Pasero, C. Patrono, E. Pinca, and F. Pugliese The synovial prostaglandin system in chronic inflammatory arthritis: differential effects of sterioidal and nonsterioidal anti-inflammatory drugs Br J Pharmacol 73 1981 893 901
5. P.V. Peplow Properties and actions of non-steroidal anti-inflammatory drugs, including their effects on prostaglandin and macromolecular synthesis Prostaglandins Leukot Essent Fatty Acids 33 1988 239 252
6. M.E. Farkouh, and B.P. Greenberg An evidence-based review of the cardiovascular risks of nonstreroidal anti-inflammatory drugs Am J Cardiol 103 2009 1227 1237
7. P.A. Gladding, M.W.I. Webster, H.B. Farrell, I.S.L. Zeng, R. Park, and N. Ruijne The antiplatelet effect of six non-steroidal anti-inflammatory drugs and their pharmacodynamic interaction with aspirin in healthy volunteers Am J Cardiol 101 2008 1060 1063
8. P.A. Gurbel, K.P. Bliden, J. DiChiara, J. Newcomer, W. Weng, N.K. Neerchal, T. Gesheff, S.K. Chaganti, A. Etherington, and U.S. Tantry Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study Circulation 115 2007 3156 3164
9. J. Scheiman Balancing risks and benefits of cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs Gastroenterol Clin North Am 38 2009 305 314
10. E.M. Antman, J.S. Bennett, A. Daugherty, C. Furberg, H. Roberts, and K.A. Taubert Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association Circulation 115 2007 1634 1642
11. A. Burke, E. Smyth, and G.A. FitzGerald Analgesic-antipyretic agents: pharmacotherapy of gout L.L. Brunton, J.S. Lazo, K.L. Parker, The Pharmacological Basis of Therapeutics 11th ed. 2006 McGraw-Hill New York, New York 671 715
12. C. Huerta, J. Castellsague, C. Valas-Lorenzo, and L.A. Garca Rodrguez Nonsteroidal anti-inflammatory drugs and risk of ARF in the general population Am J Kidney Dis 45 2005 531 539
13. M.A. Moyad Review of potential risk factors for kidney (renal cell) cancer Semin Urol Oncol 19 2001 280 293
14. D.H. Solomon, J. Avorn, T. Sturmer, R.J. Glynn, H. Mogun, and S. Schneeweiss Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high risk subgroups and time course of risk Arthritis Rheum 54 2006 1378 1389
15. D.J. Graham, D. Campen, R. Hui, M. Spence, C. Cheetham, G. Levy, S. Shoor, and W.A. Ray Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study Lancet 365 2005 475 481
16. M.D.M. Haag, M.J. Bos, A. Hofman, P.J. Koudstaal, M.M.B. Breteler, and B.H.C. Stricker Cyclooxygenase selectivity of nonsteroidal anti-inflammatory drugs and risk of stroke Arch Intern Med 168 2008 1219 1224
17. C. Bombardier, L. Laine, A. Reicin, D. Shapiro, R. Burgos-Vargas, B. Davis, R. Day, M.B. Ferraz, C.J. Hawkey, M.C. Hochberg, T.K. Kvien, T.J. Schnitzer VIGOR Study Group Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis N Engl J Med 343 2000 1520 1528
18. L.E. Levesque, J.M. Brophy, and B. Zhang The risk for myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults Ann Intern Med 142 2005 481 489
19. D.J. Kerr, J.A. Dunn, M.J. Langman, J.L. Smith, R.S. Midgley, A. Stanley, J.C. Stokes, P. Julier, C. Iveson, R. Duvvuri, C.C. McConkey VIGOR Trial Group Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer N Engl J Med 357 2007 360 369
20. M. Mamdani, D.N. Juurlink, D.S. Lee, P.A. Rochon, A. Kopp, G. Naglie, P.C. Austin, A. Laupacis, and T.A. Stukel Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study Lancet 363 2004 1751 1756
21. L.J. Crofford, P.E. Lipsky, P. Brooks, S.B. Abramson, L.S. Simon, and L.B.A. Van de Putte Basic biology and clinical application of specific cyclooxygenase-2 inhibitors Arthritis Rheum 43 2000 4 13
22. F.E. Silverstein, G. Faich, J.L. Goldstein, L.S. Simon, T. Pincus, A. Whelton, R. Makuch, G. Eisen, N.M. Agrawal, W.F. Stenson, A.M. Burr, W.W. Zhao, J.D. Kent, J.B. Lefkowith, K.M. Verburg, and G.S. Geis Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial JAMA 284 2000 1247 1255
23. Antiplatelet Trialists' Collaboration Collaborative overview of randomized trials of antiplatelet treatment I: prevention of cardiovascular death, MI and stroke by prolonged antiplatelet therapy in different categories of patients BMJ 308 1994 81 106
24. R.S. Eidelman, P.R. Herbert, S.M. Weisman, and C.H. Hennekens An update on aspirin in the primary prevention of cardiovascular disease Arch Intern Med 163 2003 2006 2010
25. F. Catella-Lawson, M.P. Reilly, S.C. Kapoor, A.J. Cucchiara, S. DeMarco, B. Tournier, S.N. Vyas, and G.A. FitzGerald Cyclooxygenase inhibitors and the antiplatelet effects of aspirin N Engl J Med 345 2001 1809 1817
26. L.E. Targownik, C.J. Metge, S. Leung, and D.G. Chateau The relative efficacies of gastroprotective strategies in chronic users of nonsteroidal anti-inflammatory drugs Gastroenterology 134 2008 937 944
27. M. Oitate, T. Hirota, K. Koyama, S. Inoue, K. Kawai, and T. Ikeda Covalent binding of radioactivity from 14 C rofecoxib, but not 14 C celecoxib or 14 C CS-706, to the arterial elastic of rats JPET 34 2006 1417 1422
28. M. Oitate, T. Hirota, M. Takahashi, T. Murai, S. Miura, A. Senoo, T. Hosokawa, T. Oonishi, and T. Ikeda Mechanism for covalent binding of rofecoxib to elastin of rat aorta JPET 320 2007 1195 1203
29. J. Steffel, M. Hermann, H. Greutert, S. Gay, T.F. Luscher, F. Ruschitzka, and F.C. Tanner Celecoxib decreases endothelial tissue factor expression through inhibition of c-jun terminal NH 2 kinase phosphorylation Circulation 111 2005 1685 1689
30. N.V. Chandrasekharan, H. Dai, L.T. Roos, N.K. Evanson, J. Tomsik, T.S. Elton, and D.L. Simmons COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression Proc Natl Acad Sci U S A 99 2002 13926 13931
31. R.M. Botting Mechanism of action of acetaminophen: is there a cyclooxygenase 3? Clin Infect Dis 31 2000 8202 8210
32. R.J. Flower, and J.R. Vane Inhibition of prostaglandin synthetase in brain explains the anti-pyretic activity of paracetamol (4-acetamidophenol) Nature (London) 240 1972 410 411
33. L. Laine, W.B. White, A. Rostom, and M. Hochberg COX-2 selective inhibitors in the treatment of osteoarthritis Semin Arthritis Rheum 38 2007 165 187
34. E.D. Hogestatt, B.A. Jnsson, A. Ermund, D.A. Andersson, H. Bjrk, J.P. Alexander, B.F. Cravatt, A.I. Basbaum, and P.M. Zygmunt Conversion of acetaminophen to the bioactive N-acyphenolamine AM404 via fatty acid amide hydrolase-dependent arachidonic conjunction in the nervous system J Biol Chem 280 2005 21405 21412
35. S.D. Solomon, M.A. Pfeffer, J.J. McMurray, R. Fowler, P. Finn, B.Bernard Levin Levin, C. Eagle, E. Hawk, M. Lechuga, A.G. Zauber, M.M. Bertagnolli, N. Arber, J. Wittes APC and PreSAP Trial Investigators Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas Circulation 114 2006 1028 1035
36. S.D. Solomon, J.J. McMurray, M.A. Pfeffer, J. Wittes, R. Fowler, P. Finn, W.F. Anderson, A.G. Zauber, E. Hawk, M.M. Bertagnolli, N. Arber Adenoma Prevention With Celecoxib (A.P.C.) Study Investigators Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention N Engl J Med 352 2005 1071 1080
37. ADAPT Research Group Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT) PLoS Clin Trials 1 2006 e33
38. R.W. Moskowitz Osteoarthritis: simple analgesics versus nonsteroidal anti-inflammatory drugs J Rheumatol 28 2001 932 934
39. R.S. Bresalier, R.S. Sandler, H. Quan, J.A. Bolognese, B. Oxenius, K. Horgan, C. Lines, R. Riddell, D. Morton, A. Lanas, M.A. Konstam, J.A. Baron Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial N Engl J Med 352 2005 1092 1102
40. E.R. Cox, M. Frisse, A. Behm, and K.A. Fariman Over-the-counter pain reliever and aspirin use within a sample of long-term cyclooxygenase 2 users Arch Intern Med 164 2004 1243 1246
41. D.H. Solomon, E.W. Karlson, E.B. Rimm, C.C. Cannuscio, L.A. Mandl, J.E. Manson, M.J. Stampfer, and G.C. Curhan Cardiovascular morbidity and mortality in women associated with rheumatoid arthritis Circulation 107 2003 1303 1307
42. J. Hippisley-Cox, and C. Coupland Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis BMJ 330 2005 13661342
43. C.P. Cannon, S.P. Curtis, G.A. FitzGerald, H. Krum, A. Kaur, J.A. Bolognese, A.S. Reicin, C. Bombardier, M.E. Weinblatt, D. van der Heijde, E. Erdmann, L. Laine MEDAL Steering Committee Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-Term (MEDAL) programme: a randomised comparison Lancet 368 2006 1771 1781 (Pubitemid 44739003)
44. M.E. Farkouh, H. Kirshner, R.A. Harrington, S.D. Ruland, F.W.A. Verheugt, T.J. Schnitzer, G.R. Burmester, E. Mysler, M.C. Hochberg, M. Doherty, E. Ehrsam, X. Gitton, G. Krammer, B. Mellein, A. Gimona, P. Matchaba, C.J. Hawkey, and J.H. Chesebro Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial Lancet 364 2004 675 684 (Pubitemid 39140623)
45. C.L. Roumie, E.F. Mitchel Jr, L. Kaltenbach, P.G. Arbogast, P. Gideon, and M.R. Griffin Nonaspirin NSAIDs, cyclooxygenase 2 inhibitors, and the risk for stroke Stroke 39 2008 2037 2045
46. S. Bak, M. Andersen, I. Tsiropoulous, L.A. Garcia Rodriguez, J. Hallas, K. Christensen, and D. Gaist Risk of stroke associated with nonsteroidal anti-inflammatory drugs: a nested case-control study Stroke 34 2003 379 386
47. W.B. White Defining the problem of treating the patient with hypertension and arthritis pain Am J Med 122 2009 S3 S9
48. D.M. Clive, and J.S. Stoff Renal syndromes associated with nonsteroidal antiinflammatory drugs N Engl J Med 310 1984 563 572
49. A. Whelton, and C.W. Hamilton Nonsteroidal anti-inflammatory drugs: effects on kidney function J Clin Pharmacol 31 1991 588 598
50. R.C. Harris, and M.D. Breyer Arachidonic acid metabolites and the kidney B.M. Brenner, Brenner and Rector's The Kidney 7th ed. 2004 W. B. Saunders St. Louis, Missouri 727 761
51. J.M. Evans, E. McGregor, A.D. McMahon, M.M. McGilchrist, M.C. Jones, G. White, D.G. McDevitt, and T.M. MacDonald Non-steroidal anti-inflammatory drugs and hospitalization for acute renal failure Q J Med 88 1995 551 557
52. S. Perez Gutthann, L.A. Garca Rodrguez, D.S. Raiford, A. Duque Oliart, and J. Ris Romeu Nonsteroidal anti-inflammatory drugs and the risk of hospitalization for acute renal failure Arch Intern Med 156 1996 2433 2439
53. M.R. Griffin, A. Yared, and W.A. Ray Nonsteroidal antiinflammatory drugs and acute renal failure in elderly persons Am J Epidemiol 151 2000 488 496
54. M. Hermann, G. Camici, A. Fratton, D. Hurlimann, F.C. Tanner, J.P. Hellerman, M. Fiedler, J. Thiery, M. Neidhart, R.E. Gay, S. Gay, T.F. Lscher, and F. Ruschitzka Differential effects of selective cyclooxygenase-2 inhibitors on endothelial function in salt-induced hypertension Circulation 108 2003 2308 2311
55. A. Whelton, W.B. White, A.E. Bello, J.A. Puma, J.G. Fort SUCCESS-VII Investigators Effects of celecoxib and rofecoxib on blood pressure and edema in patients <65 years of age with systemic hypertension and osteoarthritis Am J Cardiol 90 2002 959 963
56. W.B. White, T.J. Schnitzer, R. Fleming, B. Duquesroix, and M. Beekman Effects of the cyclooxygenase inhibiting nitric oxide donator naproxcinod versus naproxen on systemic blood pressure in patients with osteoarthritis Am J Cardiol 104 2009 840 845
57. G.H. Gilslason, J.N. Rasmussen, S.Z. Abildstrom, T.K. Schramm, M.L. Hansen, E.L. Fosbol, R. Sorenson, F. Folke, P. Buch, N. Gadsboll, S. Rasmussen, H.E. Poulsen, L. Køber, M. Madsen, and C. Torp-Pedersen Increased mortality and cardiovascular mortality associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure Arch Intern Med 169 2009 141 149
58. A. Whelton, G. Schulman, C. Wallemark, E.J. Drower, P.C. Isakson, K.M. Verburg, and S. Geis Effects of celecoxib and naproxen on renal function in the elderly Arch Intern Med 160 2000 1465 1470
59. C.H. Beck Changes in renal function with aging Clin Geriatr Med 14 1998 199 209
60. D.C. Brater Anti-inflammatory agents and renal function Semin Arthritis Rheum 32 2002 S33 S42
61. S.M. Cohen, T. Shirai, and G. Steineck Epidemiology and etiology of premalignant and malignant urothelial changes Scand J Urol Nephrol Suppl 205 2000 105 115 (Pubitemid 32056470)
62. G.G. Graham, R.I. Graham, and R.O. Day Comparative analgesia, cardiovascular and renal effects of celecoxib, rofecoxib, and acetaminophen (paracetamol) Curr Pharm Des 2 2002 1063 1075
63. J. Zhang, E.L. Ding, and Y. Song Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials JAMA 296 2006 1619 1632
64. L.A. Garcia Rodriguez, and H. Jick Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs Lancet 343 1994 769 772
65. C.H. Hennekens, M.L. Dyken, and V. Fuster Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals from the American Heart Association Circulation 96 1997 2751 2753
66. United States Preventive Services Task Force Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement Ann Intern Med 150 2009 396 404
67. United States Preventive Services Task Force Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S. Preventive Services Task Force Ann Intern Med 150 2009 405 410
68. G.A. FitzGerald, and C. Patrono The coxibs, selective inhibitors of cyclooxygenase-2 N Engl J Med 345 2001 433 442
69. T.M. MacDonald, and L. Wei Is there an interaction between the cardiovascular protective effects of low-dose aspirin and ibuprofen? Basic Clin Pharmacol Toxicol 98 2006 275 280
70. K.D. Wilner, M. Rushing, C. Walden, R. Adler, J. Eskra, R. Noveck, and R. Vargas Celecoxib does not affect the antiplatelet activity of aspirin in healthy volunteers J Clin Pharmacol 42 2002 1027 1030
71. S.E. Kimmel, J.A. Berlin, M. Reilly, J. Jaskowiak, L. Kishel, and B.L. Strom Lower myocardial infarction risk amongst current users of non-aspirin nonsteroidal anti-inflammatory medications [abstract] J Am Coll Cardiol 39 2002 318A
72. G.A. FitzGerald Parsing an enigma: the pharmacodynamics of aspirin resistance Lancet 361 2003 573 574
73. W.A. Ray, C.M. Stein, K. Hall, J.R. Daugherty, and M.R. Griffin Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study Lancet 359 2002 118 123
74. M.L. Capone, M.G. Sciulli, S. Tacconelli, M. Grana, E. Ricciotti, G. Renda, P. Di Gregorio, G. Merciaro, and P. Patrignani Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects J Am Coll Cardiol 45 2005 1295 1301
75. S.W. Rowlinson, J.R. Kiefer, J.J. Prusakiewicz, J.L. Pawlitz, K.R. Kozak, A.S. Kalgutkar, W.C. Stallings, R.G. Kurumbail, and L.J. Marnett A novel mechanism of cyclooxygenase-2 inhibition involving interactions with Ser-530 and Tyr-385 J Biol Chem 278 2003 45763 45769
76. United States Food and Drug Administration Analysis and recommendations for agency action regarding non-steroidal anti-inflammatory drugs and cardiovascular risk J Pain Palliat Care Pharmacother 19 2005 83 97
77. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents Circulation 118 2008 1894 1909
78. G.H. Gislason, S. Jacobsen, J.N. Rasmussen, S. Rasmussen, P. Buch, J. Friberg, T.K. Schramm, S.Z. Abildstrom, L. Køber, M. Madsen, and C. Torp-Pedersen Risk of death or reinfarction associated with use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction Circulation 113 2006 2906 2913
79. N.A. Nussmeirer, A.A. Whelton, M.T. Brown, R.M. Langford, A. Hoeft, J.L. Parlow, S.W. Boyce, and K.M. Verburg Complications of the COX-2 inhibitors parecoxib and celecoxib after cardiac surgery N Engl J Med 352 2005 1081 1091
80. S. Julius, S.E. Kjeldsen, M. Weber, H.R. Brunner, S. Ekman, L. Hansson, T. Hua, J. Laragh, G.T. McInnes, L. Mitchell, F. Plat, A. Schork, B. Smith, A. Zanchetti VALUE Trial Group Outcomes in hypertensive patients at high CV risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial Lancet 363 2004 2022 2031
81. J.M. Gaziano Nonnarcotic analgesics and hypertension Am J Cardiol 97 suppl 2006 10E 16E
82. A.G. Johnson, T.V. Nguyen, and R.O. Day Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis Ann Intern Med 121 1994 289 300
83. J.E. Pope, J.J. Anderson, and D.T. Felson A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure Arch Intern Med 153 1993 477 484
84. W.B. White Cardiovascular effects of the cyclooxygenase inhibitors Hypertension 49 2007 408 418
85. R. Chenevard, D. Hrlimann, M. Bchir, F. Enseleit, L. Spieker, M. Hermann, W. Riesen, S. Gay, R.E. Gay, M. Neidhart, B. Michel, T.F. Lscher, G. Noll, and F. Ruschitzka Selective COX-2 inhibition improves endothelial function in coronary artery disease Circulation 107 2003 405 409
86. A. Helin-Salmivaara, A. Virtanen, R. Vesealanin, J.M. Gronroos, T. Klaukka, J.E. Idanpaan-Heikkila, and R. Huupponen NSAID use and the risk of hospitalization for first myocardial infarction in the general population: a nationwide case-control study from Finland Eur Heart J 27 2006 1657 1663
87. American Diabetes Association Standards of medical care for patients with diabetes mellitus (position statement) Diabetes Care 24 suppl 2001 S33 S43
88. G.L. Bakris, M. Williams, L. Dworkin, W.J. Elliott, M. Epstein, R. Toto, K. Tuttle, J. Douglas, W. Hsueh, J. Sowers National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group Preserving renal function in adults with hypertension and diabetes: a consensus approach Am J Kidney Dis 36 2000 646 661
89. Antithrombotic Trialists' Collaboration Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients BMJ 324 2002 71 86
90. H.T. Sorenson, L. Mellemkjaer, W.J. Blot, G.L. Nielsen, F.H. Steffensen, J.K. McLaughlin, and J.H. Olsen Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin Am J Gastroenterol 95 2000 2218 2224
91. F.K.L. Chan, V.W. Wong, B.Y. Suen, J.C. Wu, J.Y. Ching, L.C. Hung, A.J. Hui, V.K. Sun Leung, V.W. Yan Lee, L.H. Lai, G.L. Hung Wong, D.K. Lai Chow, K.F. To, W.K. Leung, P.W. Yan Chiu, Y.T. Lee, J.Y. Wong Lau, H.L. Yuen Chan, E.K. Wai Ng, and J.J. Yiu Sung Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial Lancet 369 2007 1621 1626
92. E. Rahme, A.N. Barkun, Y. Toubouti, A. Scalera, S. Rochon, and J. Lelorier Do proton-pump inhibitors confer additional gastrointestinal protection in patients given celecoxib? Arthritis Rheum 57 2007 748 755
93. A. Aneja, and M.E. Farkouh Adverse cardiovascular effects of NSAIDs: driven by blood pressure, or edema? Ther Adv Cardiovasc Dis 2 2008 53 66
94. V. Schneider, L.E. Levesque, B. Zhang, T. Hutchinson, and J.M. Brophy Association of selective and conventional nonsteroidal antiiflammatory drugs with acute renal failure: a population-based, nested case-control study Am J Epidemiol 164 2006 881 889
95. M. Epstein Aging and the kidney J Am Soc Nephrol 7 1996 1106 1122
96. R.A. Moore, S. Derry, H.J. McQuay, and J. Paling What do we know about communicating risk? A brief review and suggestion for contextualising serious, but rare, risk, and the example of COX-2 selective and non-selective NSAIDs Arthritis Res Ther 10 2005 R20 http://arthritis-research.com/content/10/1/R20 2010 Accessed on April 28
97. J.M. Scheiman, and A.M. Fendrick Summing the risk of NSAID therapy Lancet 369 2007 1580 1581
98. M.S. Lauer Aspirin for primary prevention of coronary events N Engl J Med 346 2002 1468
99. V. Strand Are COX-2 inhibitors preferable to non-selective non-steroidal anti-inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin? Lancet 370 2007 2138 2151
100. P. McGetigan, and D. Henry Cardiovascular risk and inhibition of cyclooxygenase A systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2 JAMA 296 2006 1653 1656
101. P. McGettigan, P. Han, L. Jones, D. Whitaker, and D. Henry Selective cox-2 inhibitors, NSAIDs and congestive heart failure: differences between new and recurrent cases Br J Clin Pharmacol 65 2008 927 934
102. C. Patrono, and B. Rocca Nonsteroidal antiinflammatory drugs: past, present, and future Pharmacol Res 59 2009 285 289
103. L.S. Lohmander, D. McKeith, O. Svensson, M. Malmenas, L. Bolin, A. Kalla, G. Genti, J. Szechinski, C. Ramos-Remus STAR Multinational Study Group A randomized, placebo controlled, comparative trial of the gastrointestinal safety and efficacy of AZD3582 versus naproxen in osteoarthritis Ann Rheum Dis 64 2005 449 456
104. T.J. Schnitzer, A.J. Kivitz, R.S. Lipetz, N. Sanders, and A. Hee Comparison of the COX-inhibiting nitric oxide donator AZD3582 and rofecoxib in treating the signs and symptoms of osteoarthritis of the knee Arthritis Rheum 53 2005 827 837
105. United States Food and Drug Administration Concomitant use of ibuprofen and aspirin: potential for attenuation of the anti-platelet effect of aspirin http://www.fda.gov/downloads/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/UCM161282.pdf 2009 Accessed on January 4
106. P. Insel Analgesic-Antipyretic and Antiinflammatory Agents and Drugs Employed in the Treatment of Gout J.G. Hardman, A.G. Gilman, L.E. Limbird, Goodman's & Gilman's The Pharmaceutical Basis of Therapeutics 5th ed. 1996 Mcgraw-Hill New York 617 643
107. F.L. Lanza A guideline for treatment and prevention of NSAID-induced ulcers Am J Gastroenterol 93 1998 2037 2046
108. R.D. Altman Recommendations for the medical management of osteoarthritis of the hip and knee; 2000 update Arthritis Rheum 43 2000 1905 1915
109. A. Cheema Should people on aspirin avoid ibuprofen? A review of the literature Cardiol in Review 12 2004 174 176
110. B. Cryer, R.G. Berlin, S.A. Cooper, C. Hsu, and S. Wason Double-blind, randomized, parallel, placebo-controlled study of ibuprofen effects on thromboxane B2 concentrations in aspirin-treated healthy adult volunteers Clin Ther 27 2005 185 191
111. J.P. Curtis, Y. Wang, E.L. Portnay, F.A. Masoudi, E.P. Havranek, and H.M. Krumholz Aspirin, ibuprofen, and mortality after myocardial infarction: retrospective cohort study BMJ 327 2003 1322 1333
112. L.A.G. Rodriguez Nonsteroidal antiinflammatory drugs and the risk of myocardialinfarction in the general population Circulation 109 2004 3000 3006
113. M. Hudson Anti-inflammatory drugs are associated with a decreased risk of recurrent acute myocardial infarction in patients on aspirin Arthritis Rheum 46 2002 S617 (Abstract)
114. T.N. Patel, and K.C. Goldberg Use of Aspirin and Ibuprofen Compared With Aspirin Alone and the Risk of Myocardial Infarction Arch Intern Med 164 2004 852 856
115. T.M. MacDonald, and L. Wei Effect of ibuprofen on cardioprotective effect of aspirin Lancet 361 2003 573 574
116. T. Kurth, J. Glynn, A.M. Walker, K.A. Chan, J.E. Buring, C.H. Hennekens, and J.M. Michael Gaziano Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs Circulation 108 2003 1191 1195
117. S.E. Kimmel, J.A. Berlin, M. Reilly, J. Jaskowiak, L. Kishel, J. Chittams, and B.L. Strom The effects of nonselective non-aspirin non-steroidal anti inflammatory medications on the risk of nonfatal myocardial infarction and their interaction with aspirin J Am Coll Cardiol 43 2004 985 990